Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Myriad Genetics, Danaher, Co-Diagnostics, and More

Myriad Genetics this week said it has completed the sale of certain assets and intellectual property related to its autoimmune business unit, including the Vectra rheumatoid arthritis test, to the Laboratory Corporation of America for $150 million in cash. Utah-based Myriad announced its intent to sell these assets to Labcorp in May.


Danaher said this week that its board of directors approved a regular quarterly cash dividend of $.21 per share of its common stock, payable on Oct. 29 to shareholders of record as of Sept. 30. The board also approved a quarterly cash dividend of $11.88 per share of its 4.75 percent Series A Mandatory Convertible Preferred Stock, payable on Oct. 15 to shareholders of record as of Sept. 30. It approved a quarterly cash dividend of $12.50 per share of its 5 percent Series B Mandatory Convertible Preferred Stock, payable on Oct. 15 to holders of record as of Sept. 30.


Co-Diagnostics said this week that CoSara Diagnostics, its joint venture for manufacturing and sales in India, has received clearance from India's Central Drugs Standard Control Organization to manufacture and sell its Saragene RT-PCR in vitro diagnostic tests for the dengue and chikungunya viruses. The Saragene test kits use Co-Diagnostics' CoPrimer technology for the qualitative detection of the mosquito-borne pathogens.


Ginkgo Bioworks Holdings went public on the New York Stock Exchange on Friday, following the merger of Ginkgo Bioworks with special purpose acquisition company Soaring Eagle Acquisition. The business combination was approved by Soaring Eagle stockholders earlier this week. Ginkgo's stock finished the first trading day up almost 7 percent, at $12.18.


Proteintech Group of Rosemont, Illinois, said last week that it has made a strategic investment of undisclosed size in Active Motif, a life science tools company focused on epigenetics. Carlsbad, California-based Active Motif said it will use the funding to expand its research and development efforts and its commercial footprint. Proteintech had already been working with Active Motif to sell their products under the Active Motif brand in China, and the companies plan to grow their partnership throughout the Asia Pacific region.

 


Konica Minolta Precision Medicine said this week that it is changing its name to Realm IDx to reflect its focus on integrated diagnostics, which brings together genomics, radiology, pathology, and artificial intelligence. Realm IDx aims to provide insights for the prediction, diagnosis, and treatment of disease. The firm is a subsidiary of Konica Minolta.


In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on GenomeWeb. 

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.